tag:blogger.com,1999:blog-7857054149675424609.post7023897542780751389..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Alnylam Escalates Liver Cancer Drug Candidate to Dose Levels Predicted to Yield Meaningful KnockdownDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-7857054149675424609.post-84082778944275056532010-11-12T03:35:02.506+00:002010-11-12T03:35:02.506+00:00It is definitely '02'. This indicates that...It is definitely '02'. This indicates that they once had a different development candidate that did not make it into the clinic. That in itself is not very remarkable, but if you read the 'VSP patent' you might speculate about the Tekmira-Alnylam relationship 2-3 years ago.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-34580887413647679702010-11-11T18:00:09.426+00:002010-11-11T18:00:09.426+00:00Dirk
In your Alnylam article, you indicate it was...Dirk<br /><br />In your Alnylam article, you indicate it was ALN-VSP02. Are you sure it was VSP02? From Alnylam's press release, I thought it was VSP01. In Alnylam's press release, they said: "About ALN-VSP Clinical Program -- ALN-VSP is Alnylam's first systemic RNAi program and represents the company's first clinical program in oncology. The drug is formulated in a first Anonymousnoreply@blogger.com